The acquired resistance to BRAFi through the reactivation of the MAPK pathway, occurring upstream, downstream or at the BRAF level, plays a crucial role in the majority of patients affected by advanced melanoma due to the relatively short PFS observed when treated with BRAFi alone. The gene discussed is BRAF; the disease is melanoma.